SNIPER (ABL) -019
SNIPER (ABL) -019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM[1].
Product Specifications
UNSPSC
12352005
Target
Bcr-Abl; SNIPERs
Type
Reference compound
Related Pathways
PROTAC; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sniper-abl-019.html
Solubility
10 mM in DMSO
Smiles
CC1=C(NC(C2=CN=C(NC3=CC(N4CCN(C(COCCOCCOCCNC([C@H](C(C5=CC=CC=C5)C6=CC=CC=C6)NC([C@H]7N(C([C@@H](NC([C@H](C)NC)=O)C8CCCCC8)=O)CCC7)=O)=O)=O)CC4)=NC(C)=N3)S2)=O)C(Cl)=CC=C1
Molecular Formula
C60H77ClN12O9S
Molecular Weight
1177.85
References & Citations
[1]Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108 (8) :1657-1666.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS9246955-02 5x 0.1 mg
Anti-CD19 Reference Antibody (denintuzumab)
Sign In for Pricing
View Details 
